Population pharmacokinetics of ruxolitinib in children with hemophagocytic lymphohistiocytosis: focus on the drug–drug interactions

Ruxolitinib dosing for acute graft‐versus‐host disease in a pediatric patient receiving continuous renal replacement therapy

“…3 Our institutional protocol calls for a 50% ruxolitinib dose reduction when given concomitantly with a strong CYP3A4 inhibitor. [4][5] Ruxolitinib is 74% excreted by the kidneys so a reduced dose of 5 mg once daily is recommended for creatinine clearance < 15 mL/minute or once after each dialysis session for patients on intermittent hemodialysis (iHD). Although the parent drug is not removed by dialysis, the metabolites are dialyzable to varying degrees, likely prolonging their half-lives in a patient on dialysis.…”